Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22140
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTiihonen, J.en
dc.contributor.authorWahlbeck, K.en
dc.contributor.authorLonnqvist, J.en
dc.contributor.authorKlaukka, T.en
dc.contributor.authorIoannidis, J. P.en
dc.contributor.authorVolavka, J.en
dc.contributor.authorHaukka, J.en
dc.date.accessioned2015-11-24T19:22:03Z-
dc.date.available2015-11-24T19:22:03Z-
dc.identifier.issn1756-1833-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22140-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntipsychotic Agents/*therapeutic useen
dc.subjectCohort Studiesen
dc.subjectCommunity Mental Health Services/statistics & numerical dataen
dc.subjectFemaleen
dc.subjectFinland/epidemiologyen
dc.subjectHumansen
dc.subjectLength of Stayen
dc.subjectMaleen
dc.subjectPatient Readmission/statistics & numerical dataen
dc.subjectProspective Studiesen
dc.subjectPsychotic Disorders/*drug therapy/mortalityen
dc.subjectRisk Factorsen
dc.subjectSchizophrenia/*drug therapy/mortalityen
dc.subjectTreatment Outcomeen
dc.subjectTreatment Refusalen
dc.titleEffectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1136/bmj.38881.382755.2F-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16825203-
heal.identifier.secondaryhttp://www.bmj.com/highwire/filestream/375777/field_highwire_article_pdf/0-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2006-
heal.abstractOBJECTIVE: To study the association between prescribed antipsychotic drugs and outcome in schizophrenia or schizoaffective disorder in the community. DESIGN: Prospective cohort study using national central registers. SETTING: Community care in Finland. PARTICIPANTS: Nationwide cohort of 2230 consecutive adults hospitalised in Finland for the first time because of schizophrenia or schizoaffective disorder, January 1995 to December 2001. MAIN OUTCOME MEASURES: Rates of discontinuation of drugs (all causes), rates of rehospitalisation, and mortality associated with monotherapy with the 10 most commonly used antipsychotic drugs. Multivariate models and propensity score methods were used to adjust estimates of effectiveness. RESULTS: Initial use of clozapine (adjusted relative risk 0.17, 95% confidence interval 0.10 to 0.29), perphenazine depot (0.24, 0.13 to 0.47), and olanzapine (0.35, 0.18 to 0.71) were associated with the lowest rates of discontinuation for any reason when compared with oral haloperidol. During an average follow-up of 3.6 years, 4640 cases of rehospitalisation were recorded. Current use of perphenazine depot (0.32, 0.22 to 0.49), olanzapine (0.54, 0.41 to 0.71), and clozapine (0.64, 0.48 to 0.85) were associated with the lowest risk of rehospitalisation. Use of haloperidol was associated with a poor outcome among women. Mortality was markedly raised in patients not taking antipsychotics (12.3, 6.0 to 24.1) and the risk of suicide was high (37.4, 5.1 to 276). CONCLUSIONS: The effectiveness of first and second generation antipsychotics varies greatly in the community. Patients treated with perphenazine depot, clozapine, or olanzapine have a substantially lower risk of rehospitalisation or discontinuation (for any reason) of their initial treatment than do patients treated with haloperidol. Excess mortality is seen mostly in patients not using antipsychotic drugs.en
heal.journalNameBMJen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Tiihonen-2006-Effectiveness of ant.pdf105.2 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons